Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/6/2019
SIETES contiene 92761 citas

 
 
<< anterior 21 a 40 de 129 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Thorlund K, Druyts E, Wu P, Balijepalli C, Keohane D, Mills E. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 2015;63:1002-9. [Ref.ID 99078]
22.Tiene citas relacionadas Cita con resumen
23.Tiene citas relacionadas Cita con resumen
Maund E, Tendal B, Hróbjartsson A, Jorgensen KJ, Lundh A, Schroll J, Gotzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ 2014;348:g3510. [Ref.ID 98036]
24.Tiene citas relacionadas Cita con resumen
Doshi P, Zito J, dosReis S. Digging for data on harms in duloxetine trials. BMJ 2014;348:g3578. [Ref.ID 98035]
25. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626. [Ref.ID 97343]
26.Tiene citas relacionadas
Moore A, Wiffen P, Eccleston Ch, Lunn M, Hughes R, Williams A, Aldington D, Kalso E. Duloxetine: Andrew Moore and colleagues reply to Des Spence. BMJ 2014;348:g1490. [Ref.ID 97331]
27.Tiene citas relacionadas Cita con resumen
Spence D. Bad medicine: the rise of duloxetine. BMJ 2014;348:g139. [Ref.ID 97247]
28.Tiene citas relacionadas Cita con resumen
Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]
29. Cita con resumen
Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti M, De Ponti F. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur J Clin Pharmacol 2013;69:2095-101. [Ref.ID 96640]
30. Cita con resumen
Anónimo. Drug-induced liver injury. Australian Prescriber 2013;36:168-9. [Ref.ID 96320]
31. Cita con resumen
Anónimo. Duloxétine: syndromes de sevrage. Prescrire 2013;33:517. [Ref.ID 95944]
32. Cita con resumen
Iriarte Cerdán M, Ágreda Peiró J. Dolor neuropático. AMF 2013;9:340-5. [Ref.ID 95667]
33. Cita con resumen
Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry 2013;170:651-9. [Ref.ID 95640]
34. Cita con resumen
Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, for the Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. A randomized clinical trial. JAMA 2013;309:1359-67. [Ref.ID 95235]
35. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
36.Tiene citas relacionadas Cita con resumen
Ioannidis JPA. Mega-trials for blockbusters. JAMA 2013;309:239-40. [Ref.ID 94781]
38.
Anónimo. An update on the drug treatment of neuropathic pain. Part 1: antidepressants. Drug Ther Bull 2012;50:114-7. [Ref.ID 93823]
39. Cita con resumen
Anónimo. Serotonergic medicines. Risk of reversible cerebral vasoconstriction syndrome (RCVS). New Zealand. WHO Pharmaceuticals Newsletter 2012;4:11-2. [Ref.ID 93679]
40. Cita con resumen
Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, Wilson JP. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol 2012;68:1295-302. [Ref.ID 93647]
Seleccionar todas
 
<< anterior 21 a 40 de 129 siguiente >>